Rubius Therapeutics Stock Revenue
| RUBYDelisted Stock | USD 0.08 0.02 17.00% |
Rubius Therapeutics fundamentals help investors to digest information that contributes to Rubius Therapeutics' financial success or failures. It also enables traders to predict the movement of Rubius Pink Sheet. The fundamental analysis module provides a way to measure Rubius Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rubius Therapeutics pink sheet.
Rubius |
Rubius Therapeutics Company Revenue Analysis
Rubius Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
CompetitionBased on the latest financial disclosure, Rubius Therapeutics reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Rubius Therapeutics is currently under evaluation in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 0.0. Rubius Therapeutics adds roughly 0.0 in revenue claiming only tiny portion of equities under Health Care industry.Rubius Fundamentals
| Return On Equity | -1.85 | |||
| Return On Asset | -0.47 | |||
| Current Valuation | 22.18 M | |||
| Shares Outstanding | 90.4 M | |||
| Shares Owned By Insiders | 5.55 % | |||
| Shares Owned By Institutions | 72.61 % | |||
| Number Of Shares Shorted | 1.53 M | |||
| Price To Book | 0.42 X | |||
| EBITDA | (169.55 M) | |||
| Net Income | (179.67 M) | |||
| Cash And Equivalents | 140.71 M | |||
| Cash Per Share | 1.56 X | |||
| Total Debt | 76.15 M | |||
| Debt To Equity | 1.17 % | |||
| Current Ratio | 4.63 X | |||
| Book Value Per Share | 0.17 X | |||
| Cash Flow From Operations | (150.14 M) | |||
| Short Ratio | 0.49 X | |||
| Earnings Per Share | (2.27) X | |||
| Target Price | 1.0 | |||
| Number Of Employees | 20 | |||
| Beta | 2.45 | |||
| Market Capitalization | 7.5 M | |||
| Total Asset | 23.07 M | |||
| Z Score | -23.1 | |||
| Net Asset | 23.07 M |
About Rubius Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rubius Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rubius Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rubius Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in Rubius Pink Sheet
If you are still planning to invest in Rubius Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rubius Therapeutics' history and understand the potential risks before investing.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |